Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.

Suppr

超能文献

作者信息

Hameed Omar, Chhieng David, Adams Amy L

出版信息

J Clin Oncol. 2008 Mar 20;26(9):1571. doi: 10.1200/JCO.2008.16.6868.

DOI:10.1200/JCO.2008.16.6868

PMID:18349417

Abstract

摘要

相似文献

Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.

J Clin Oncol. 2008 Mar 20;26(9):1571. doi: 10.1200/JCO.2008.16.6868.

Human epidermal growth factor receptor 2 testing in breast cancer.

J Clin Oncol. 2007 Sep 1;25(25):4020; author reply 4021-3. doi: 10.1200/JCO.2007.10.8522.

Human epidermal growth factor receptor 2 testing recommendation.

J Clin Oncol. 2007 Sep 1;25(25):4020-1; author reply 4021-3. doi: 10.1200/JCO.2007.11.7580.

HER2 testing: current status and future directions.

Cancer Treat Rev. 2014 Mar;40(2):276-84. doi: 10.1016/j.ctrv.2013.09.001. Epub 2013 Sep 11.

Lapatinib study supports cancer stem cell hypothesis, encourages industry research.

J Natl Cancer Inst. 2008 May 21;100(10):694-5. doi: 10.1093/jnci/djn168. Epub 2008 May 13.

Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.

Cancer. 2005 Feb 1;103(3):442-3. doi: 10.1002/cncr.20813.

Clinical significance of basal-like subtype in triple-negative breast cancer.

Breast Cancer. 2009;16(4):260-7. doi: 10.1007/s12282-009-0150-8. Epub 2009 Aug 22.

Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.

J Natl Cancer Inst. 2008 Jun 18;100(12):836-7, 844. doi: 10.1093/jnci/djn200. Epub 2008 Jun 10.

Clinical practice patterns and cost-effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.

Cancer. 2010 Aug 15;116(16):3980-1; author reply 3981. doi: 10.1002/cncr.25186.

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

BMC Cancer. 2008 Oct 23;8:307. doi: 10.1186/1471-2407-8-307.

引用本文的文献

Twenty-five years with HER2 targeted therapy.

Ann Transl Med. 2024 Jun 10;12(3):53. doi: 10.21037/atm-23-153. Epub 2023 Jun 25.

A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer.

Front Oncol. 2021 Jul 23;11:676939. doi: 10.3389/fonc.2021.676939. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.

J Clin Oncol. 2008 Mar 20;26(9):1571. doi: 10.1200/JCO.2008.16.6868.

Human epidermal growth factor receptor 2 testing in breast cancer.

J Clin Oncol. 2007 Sep 1;25(25):4020; author reply 4021-3. doi: 10.1200/JCO.2007.10.8522.

Human epidermal growth factor receptor 2 testing recommendation.

J Clin Oncol. 2007 Sep 1;25(25):4020-1; author reply 4021-3. doi: 10.1200/JCO.2007.11.7580.

HER2 testing: current status and future directions.

Cancer Treat Rev. 2014 Mar;40(2):276-84. doi: 10.1016/j.ctrv.2013.09.001. Epub 2013 Sep 11.

Lapatinib study supports cancer stem cell hypothesis, encourages industry research.

J Natl Cancer Inst. 2008 May 21;100(10):694-5. doi: 10.1093/jnci/djn168. Epub 2008 May 13.

Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.

Cancer. 2005 Feb 1;103(3):442-3. doi: 10.1002/cncr.20813.

Clinical significance of basal-like subtype in triple-negative breast cancer.

Breast Cancer. 2009;16(4):260-7. doi: 10.1007/s12282-009-0150-8. Epub 2009 Aug 22.

Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.

J Natl Cancer Inst. 2008 Jun 18;100(12):836-7, 844. doi: 10.1093/jnci/djn200. Epub 2008 Jun 10.

Clinical practice patterns and cost-effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.

Cancer. 2010 Aug 15;116(16):3980-1; author reply 3981. doi: 10.1002/cncr.25186.

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

BMC Cancer. 2008 Oct 23;8:307. doi: 10.1186/1471-2407-8-307.

引用本文的文献

Twenty-five years with HER2 targeted therapy.

Ann Transl Med. 2024 Jun 10;12(3):53. doi: 10.21037/atm-23-153. Epub 2023 Jun 25.

A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer.

Front Oncol. 2021 Jul 23;11:676939. doi: 10.3389/fonc.2021.676939. eCollection 2021.